Current treatments for atrial fibrillation (AFib), a common heart condition characterized by fast and irregular beats that can lead to stroke and heart failure, have multiple side effects and are ineffective for preventing AFib recurrence.
FDA approves Skyline Therapeutics’ IND for macular degeneration trial – Pharmaceutical Technology
nAMD, which leads to severe visual impairment, is estimated to affect over 200 million people worldwide. Image credit: Shutterstock/air009. Chinese gene therapy company Skyline will